"HIV-1 Gag-specific exosome-targted T cell-based vaccine stimulates effector CTL responses leading to therapeutic and long-term immunity against Gag/HLA-A2-expressing B16 melanoma in transgenic HLA-A2 mice."
Authors: Wang R, Xie Y, Zhao T, Tan X, Xu J and Xiang J.
Trials in Vaccinol, 3: 19-25, 2014.
The paper can be accessed here: http://www.sciencedirect.com/science/article/pii/S1879437813000181
Share this story